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1. Introduction 
Pancreatic cancer, which we refer to pancreatic ductal adenocarcinoma, is the forth most 
common cause of cancer-realated-death disease. In 2010, there were 43,140 new cases and 
36,800 patients died of pancreatic cancer in USA(1). Although surgical resection may be the 
only available treatment for this horrible disease, there are beyond 80% patients when 
dignosised cannot be cured by surgical treatment(2). In the past 50 years, despite of the 
progress in surgery skill, hospital morbidity and mortality rates were decreased from 59% 
and 24% to 36% and 2%, respectively(3) , in the patients received the most optimal surgical 
operation, the median survival ranged from 15 to 19 months, and 5-year survival rate was 
still approximately 20%(4). Even if Gemcitabine became the new standard of chemotherapy 
in pancreatic cancer in 1997(5). The outcome of the pancreatic cancer is still dismal, overall 
five-year survival rate is blow 5%. With an increasing incidence of pancreatic cancer in the 
world and conventional treatments often have limited effects and substantial toxicity, a 
strong need exists for novel therapies. Biological approaches, including gene therapy and 
immunotherapy, which are targeting pancreatic cancer at a molecular or protein level, are 
rapidly evolving and seem to be promising strategies for this devastating and virtually 
unexceptionally lethal malignancy.  
2. Immune target and Immune response in pancreatic cancer 
Cancer is fundamentally a gene associated disease, it has become increasingly clear that 
some genomic instability and aberrant gene expression lead to biologic behaviour 
abnormality in tumor cells. In pancreatic cancer, Several genes have high mutation rate in 
different phase, so the tumor cell may express abnormal antigens that make them 
immunologically distinct and potential targets for the host immune system. 
K-Ras: The mutation of K-ras oncogene (homologous to the ras gene of Kirsten murine 
sarcoma virus) occurs in 75-100% of pancreatic cancer(6). With the progression from 
minimally dysplasia epithelium(PanIN 1A, 1B) to more severe dysplasia(PanIN 2, 3) and 
invasive cancer(7), the mutation rate of K-ras oncogene is increaseing successively, denotes k-
ras oncogene plays a very important role in tumor origination and progression(8).  
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Picture 1. Associated genes in pancreatic cancer progression. from Paula Ghaneh, et al. 
Biology and management of pancreatic cancer. Gut 2007;56:1134-1152.  
K-ras gene encodes a 21 kDa membrane-bound guanosine triphosphate(GTP) –binding 
protein. Before localization at cell membrane, K-ras protein must be farnesylated or 
geranylgeranylated on the same cysteine residue, it is involved in the transduction of signal 
from growth factor receptors and other signal inputs, as an upstream activator, it will activat 
several signaling pathways including Raf/MEK/ERK, P13K/Akt and RalEGF/Ral(9)to 
regulate gene expression and prevent apoptosis. The mutation of the K-ras oncogene, which 
occers mostly at codon 12 but also occasionally at codon 13 and 61, will lead to impaired 
GTPhosphatase(GTPase) activity, resulting in lock the protein locked in GTP-bound state 
and thus activating downstream signalling cascades(10). According to the META Analyse, 
point mutation occurred in codon 12 mainly divided into several types, the wild type GGT 
is replaced by GAT(47%), GTT(28%), CGT(15%), TGT(7%), AGT(2%) and GCT(1%). so in the 
protein, the 12th amino acid Guanine is replaced by Aspartic acid, Valine, Arginine, 
Cysteine, Alanine, Serine(11). The K-RAS function changes due to the abnormality in protein 
structure. The mutation also provide the epitope which might be the target in 
immunotherapy.  
MUC1: Mucins are large glycoproteins with carbohydrate content and marked diversity 
both in the apoprotein and in the oligosaccharide moieties(12). MUC1 is a heavily 
glycosylated typeレmembrane protein with several extracellular tandem repeat domains, 
which is expressed by nearly all human glandular epithelial and its expression is limited to 
the apical membrane of the cells. In pancreatic cancer, MUC1 expression is upregulated with 
an expression pattern over the entire cell surface(13). The core peptide of MUC1 not only 
serves as a counter-receptor for myelin-associated glycoprotein in pancreatic cancer and is 
related to perineural invasion(14), but also block death receptor-mediated apoptosis by 
binding to caspase 8 and FADD(15). MUC1 molecular has sialic acid-containing 
oligosaccharides in a highly O-glycosylated tandem-repeat domain, the structure has wide 
range and a large molecular weight(16). Although the core protein of MUC1 is similar in both 
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normal and tumor cells, there is a remarkable diversity in oligosaccharide moieties between 
normal and cancer cells(17).  
Mesothelin: Mesothelin is a 40-kDa glycosyl phosphatidylinositol anchored cell surface 
protein and is a c-terminus menbrane-bound form of a 69-kDa precursor protein encoded by 
the Mesothelin gene(MSLN). Normally, mesothelin is only expressed on mesothelial cells 
which lining peritoneal, pleural and pericardial cavities(18). The biologic functions are not 
clearly understood. Some early studies have shown mesothelin playing role in tumor 
adhesion and dissemination(19). In pancreaticobiliary adenocarcinomas, the expression rate 
of mesotheline is 100%, whereas none in normal pancreas and chronic pancreatitis(20).  
2.1 Immune escape and immunosuppression 
In the past 50 years, with the advances in cellular, molecular biology of cancer and 
development of immunology, people comes to realizes the relationship between tumor and 
immune cells is just like a cat and mouse game. The human immune system assume the 
responsibility to get rid of the extrinsic and endogenic abnormal antigen, it can produce 
actived immunocyte or immune material such as antibody to react anomalous antigen and 
finally eliminate the target, but the fact is not under our desire. (Picture 2) 
 
Picture 2. Immune system：From Robert A. Weinberg, The Biology of Cancer. 2007 
At the genesis of the cancer, under ideal condition, the innate immune system responds to 
“danger signals”, macrophages and fibroblasts are enlisted to construct the 
microenvironment surrounding the cancer cell, just like inflmmation, many cytokines and 
growth factors are produced to activate innate effector cells with antitumor activity, 
stimulate professional antigen-presenting cells (APCs, mainly dendritic cell) to capture 
tumor-derived antigens and migrate to draining lymph nodes to priming an adaptive 
response by activating T and B lymphocytes. Unfortunately, the growth factors can also 
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stimulate cancer cells proliferation and progression. The cancer cells are so clever that can 
learn to avoid detection or to escape or overwhelm the immune response. 
Immunosuppressive tumor-associated macrophages (TAMs), myeloid-derived suppressor 
cells (MDSC), and regulatory T cells (Treg) reside in tumors, and their products along with 
tumor derived products (such as VEGF, TGFbeta and IL-10), create a microenvironment that 
resists immune activation and attack.  
Many strategies are found to escape from immune surveillance(21). 1) Physical exclusion of 
immune cells from tumor site. It has been proved in epithelial cancer that basal-membrane-
like structures around the tumor can prevent lymphocytes from infiltrating and tumor-
specific T cells expanding(22). 2) Poor immunogenicity by reducing expression of major 
histocompatability complex(MHC) or co-stimulatory proteins(23) and disruption of natural 
killer(NK) and natural killer T (NKT) cell recognition(24). The other ways are to change 
themselves by losing whole protein or TAA expression, which changes in immunodominant 
T-cell epitopes that alter T-cell recognition, antigen processing or binging to the MHC. 3) 
Secreting soluble immunosuppressive proteins such as interleukin (IL-10) to prevent 
inflammatory response from triggering, or vascular endothelial growth factor(VEGF) to 
interfere with dendritic cells(DC) activation and differentiation(25). 4) Increasing expression 
of STAT3 protein to block the production of pro-inflammatory molecules(26).  
If the specific reaction had been established, being attacked by activated NK cells, antibodies 
or cytotoxic T lymphocytes, cancer cells can escape elimination according to down-
regulating targeted antigens, rendering tuomr-reative cell anergic(27), or inducing 
responding T cell apotosis specifically. The pro-apoptotic function of FasL on carcinoma 
cells has been demonstrated in both in virto and in vivo, FasL expressed cancer cells can 
induce apoptosis of lymphocytes in Fas-dependent manner(28), and in patient’s biopsies, the 
present of FasL on cancer cells is in parallel with reduced number(29) and apoptosis (30)of 
tumor-infiltrating immune cells (TICs). In pancreatic ductal carcinoma, the expression of 
FasL is 82% in primary versus 100% in hepatic metastases and is associate with shorter 
survival(31). At last, the eventual developed tumor reflects immunoediting with selection of 
poorly immunogenic and/or immune-resistant malignant cells(32). 
Treg cells: CD4+25+Foxp3+ regulatory T cells (Tregs) have been discovered in the 1960s, 
which can suppres T-cell response and compromise the development of effective tumor 
immunity(33). these cells are distinguished in high expressed CD4, CD25, CTLA-4, the 
glucocorticoid-induced TNF-related receptor (GITR) and the forkhead transcription Foxp3. 
they can arise in response to persistent antigen stimulation in the absence of inflammatory 
signals, especially in the presence of TGF-ǃ(34). The tumor-induced expansion of regulatory T 
cells by conversion of CD4+CD25+ lymphocytes is thymus and proliferation 
independent(35).  
Tregs play a critical role in the induction of tolerance to tumor-associated antigens and 
suppression of antitumor immunity. Additional evidence showed that Tregs were increased 
locally within the tumor microenvironment by a mechanism that seems dependent on TGF-
beta receptor expression and the presence of tumor derived TGF-beta. The murine pancreas 
cancer cell line Pan02 produces high levels of TGF-beta both in vitro and in vivo. In contrast, 
the esophageal murine cancer cell line, Eso2, does not. Immunohistochemical staining of 
Foxp3 in explanted tumors showed an identifiable population of Treg in the Pan02 (TGF-
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beta positive) tumors but not Eso2 (TGF-beta negative). Naive CD4+25-Foxp3- T cells, when 
adoptively had transferred into Rag-/- mice, were converted into Foxp3+ Treg in the 
presence of Pan02 but not Eso2 tumors. Induction of Treg in Pan02 mice was blocked by 
systemic injection of an anti-TGF-beta antibody. If Rag-/- mice were instead reconstituted 
with naive CD4+25- T cells expressing a mutated TGF-beta receptor, induction of Foxp3+ 
Treg in Pan02 bearing mice was blocked. Collectively, The observations supported the role 
of TGF-beta in the induction of Treg in pancreas adenocarcinoma(36).  
Recent studies have shown that increased numbers of tumor-infiltrating Tregs were 
associated with poorer prognosis in pancreatic cancer(37)(38), so the presence of Tregs in 
pancreatic cancers highlighes the importance of targeting the suppressive function of these 
cells in future immunotherapy research.  
In Yamamoto’s study, a cytotoxicity assay, enzyme-linked immunosorbent spot (ELISPOT) 
assay and measuring cytokine secretion, were used to study the efficacy of Treg depletion 
by anti-CD25 antibody added to a dendritic cell/tumor cell (DC/TC) fusion hybrid vaccine 
in a murine pancreatic cancer model. All the mice treated with the combined therapy of 
fusion hybrid vaccine and Treg depletion rejected tumor growth in a challenging test, 
although the rejection rate was 20% both for mice that received the fusion hybrids alone or 
Treg depletion alone. In addition, combined therapy showed a significantly improved 
survival in comparison to other treatment or control groups. The NK cell activity for DC/TC 
fusion + Treg depletion was significantly higher than that for the other treatment groups. 
Cytotoxic T lymphocyte (CTL) activity for DC/TC could potentially be enhanced by the 
addition of Treg depletion therapy. The treatments including DC/TC fusion induced IFN-
gamma secreting effector cells in ELISPOT assays. Furthermore, a cytometric beads array 
assay used to measure cytokine secretion showed that DC/TC fusion + Treg depletion 
stimulated the highest levels of IFN-gamma Th1/Th2 ratios and Th17. The results 
demonstrate that Treg depletion combined with DC/TC fusion hybrid vaccine enhanced the 
efficacy of immunotherapy in pancreatic cancer by activating CTLs and NK cells(39).  
In both human pancreatic adenocarcinoma and a murine pancreatic tumor model (Pan02), 
tumor cells produce increased levels of ligands for the CCR5 chemokine receptor and, 
reciprocally, CD4(+) Foxp3(+) Tregs, compared with CD4(+) Foxp3(-) effector T cells, 
preferentially express CCR5. When CCR5/CCL5 signaling is disrupted, either by reducing 
CCL5 production by tumor cells or by systemic administration of a CCR5 inhibitor , Treg 
migration to tumors is reduced and tumors are smaller than in control mice. Thus, the study 
demonstrates the importance of Tregs in immune evasion by tumors, how blockade of Treg 
migration might inhibit tumor growth, and, specifically in pancreatic adenocarcinoma, the 
role of CCR5 in the homing of tumor-associated Tregs. Selective targeting of CCR5/CCL5 
signaling may represent a novel immunomodulatory strategy for the treatment of cancer(40).  
In murine mesothelin-expressing pancreatic tumor model (Panc02), vaccine with the 
immune-relevant mesothelin-derived peptides and in sequence with low-dose 
cyclophosphamide (CY) and an anti-CD25 IL-2Rǂ monoclonal antibody (PC61), which are 
known to deplete subpopulations of T regulatory cells (Tregs), showed that combined Treg-
depleting therapies synergize to enhance vaccine efficacy(41).  
Myeloid-derived suppressor cells: Myeloid-derived suppressor cells(MDSCs) are a 
heterogeneous population of cells that expand during cancer, inflammation and infection, 
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and have a remarkable ability to suppress T-cell responses(42). They contributes negative 
regulation of immune response and can be activated by factor produced by activated T cells 
and tumor stromal cells(43).  
Myeloid derived suppressor cells (MDSC), which are observed with increased prevalence in 
the peripheral blood and tumor microenvironment of cancer patients, including pancreatic 
cancer. Accumulation of MDSC in the peripheral circulation has been related to extent of 
disease, and correlates with stage. MDSC have primarily been implicated in promoting 
tumor growth by suppressing antitumor immunity. There is also compelling evidence 
MDSC are also involved in angiogenesis and metastatic spread. Two main subsets of MDSC 
have been identified in cancer patients: a monocytic subset, characterized by expression of 
CD14, and a granulocytic subset characterized by expression of CD15. Both subsets of 
MDSC actively suppress host immunity through a variety of mechanisms including 
production of reactive oxygen species and arginase. Just as in humans, accumulation of 
monocytic and granulocytic MDSC has been noted in the bone marrow, spleen, peripheral 
circulation, and tumors of tumor bearing mice. Successful targeting of MDSC in mice is 
associated with improved immune responses, delayed tumor growth, improved survival, 
and increased efficacy of vaccine therapy. By further elucidating mechanisms of MDSC 
recruitment and maintenance in the tumor environment, strategies could be developed to 
reverse immune tolerance to tumor(44).  
In a comprehensive analysis of circulating myeloid-derived suppressor cells (MDSCs) and T 
regulatory cells (Tregs) in pancreatic, esophageal and gastric cancer Patients Peripheral 
blood was collected from 131 cancer patients (46 pancreatic, 60 esophageal and 25 gastric) 
and 54 healthy controls. PBMC were harvested with subsequent flow cytometric analysis of 
MDSC (HLADR(-) Lin1(low/-) CD33(+) CD11b(+)) and Treg (CD4(+) CD25(+) CD127 
(low/-) FoxP3(+)) percentages. MDSCs and Tregs were statistically significantly elevated in 
pancreatic, esophageal and gastric cancer compared with controls, and MDSC numbers 
correlated with Treg levels. Increasing MDSC percentage was associated with increased risk 
of death, and in a multivariate analysis, MDSC level was an independent prognostic factor 
for survival. A unit increase in MDSC percentage was associated with a 22% increased risk 
of death (hazard ratio 1. 22,95% confidence interval 1.06-1.41). The result showed MDSCs 
are an independent prognostic factor for survival(45).  
In mice with spontaneous pancreatic tumours, mice with premalignant lesions as well as 
wild-type mice, Myeloid-derived suppressor cells (MDSC)were analysed. An increase in the 
frequency of MDSC early in tumour development was detected in lymph nodes, blood and 
pancreas of mice with premalignant lesions and increased further upon tumour progression. 
The MDSC from mice with pancreatic tumours have arginase activity and suppress T-cell 
responses, which represent the hallmark functions of these cells. The study suggests that 
immune suppressor mechanisms generated by tumours exist as early as premalignant 
lesions and increase with tumour progression and highlight the importance of blocking 
these suppressor mechanisms early in the disease in developing immunotherapy 
protocols(46).  
Nagaraj reported use of the synthetic triterpenoid(CDDO-Me) can completely abrogated 
immune suppressive activity of MDSC in vitro, CDDO-Me reduced reactive oxygen species 
in MDSCs but did not affect their viability or the levels of nitric oxide and arginase. 
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Treatment of tumor-bearing mice with CDDO-Me did not affect the proportion of MDSCs in 
the spleens but eliminated their suppressive activity. This effect was independent of 
antitumor activity. CDDO-Me treatment decreased tumor growth in mice. Experiments with 
severe combined immunodeficient-beige mice indicated that this effect was largely 
mediated by the immune system. CDDO-Me substantially enhanced the antitumor effect of 
a cancer vaccines. treatment of pancreatic cancer patients with the synthetic triterpenoid 
(CDDO-Me) didn’t affect the number of MDSCs in peripheral blood but significantly 
improved the immune response. The research demonstrated MDSCs is the key of the 
immunotherapy(47).  
3. Nonspecific immunotherapy - Innate Immune system and cytokine 
Nature kill cells are the central component of the innate immunity and play an important 
role in cancer immunosurveilance. It has been reported that NK cells can recognize and 
control tumor growth by direct cellular cytotoxicity and secrete immunostimulatory 
cytokines such as IFN-Ǆ. The further researches have demonstrated NK cells can eliminate 
tumor cell by inhibiting cellular proliferation, angiogenesis, promoting apoptosis and 
stimulate the adaptive immune system. In mouse experimental models, NK cell-mediated 
elimination of tumor cells induced the subsequent development of tumor-specific T cell 
responses to the parental tumor cells as a bridge between innate and adaptive immune 
responses(48).  
In 1984, K. Funa has found patients with pancreatic adenocarcinomas expressing 
deficiencies in the NK-IFN system at least three levels:(1)diminished basal NK activities, 
(2)decreased sensitivity of NK to IFN in virto, (3)decreased atypical IFN production by 
staphylococcus aureus cowan Ⅰ(SACoI)(49).  
In a recent clinical trial, a patient exhibited regression of several pancreatic cancer 
metastases following the administration of the immune modulator Ipilimumab (anti-CTLA-
4 antibody). Tumor infiltrating lymphocytes (TIL-2742) and an autologous tumor line (TC-
2742) were expanded from a regressing metastatic lesion excised from this patient. Natural 
killer (NK) cells predominated in the TIL (92% CD56(+)) with few T cells (12% CD3(+)). A 
majority (88%) of the NK cells were CD56(bright)CD16(-). TIL-2742 secreted IFN-Ǆ and GM-
CSF following co-culture with TC-2742 and major histocompatibility complex mismatched 
pancreatic tumor lines. After sorting TIL-2742, the purified CD56(+)CD16(-)CD3(-) subset 
showed reactivity similar to TIL-2742 while the CD56(-)CD16(-)CD3(+) cells exhibited no 
tumor recognition. In co-culture assays, TIL-2742 and the NK subset expressed high 
reactivity to several pancreatic cancer cell lines and could lyse the autologous tumor as well 
as pancreas cancer lines. Reactivity was partially abrogated by blockade of TRAIL. This 
represents the first report of CD56(+)CD16(-) NK cells with apparent specificity for 
pancreatic cancer cell lines and associated with tumor regression following the treatment 
with an immune modulating agent(50).  
Clinical and experimental evidence demonstrate the extent of NK cell activity in peripheral 
blood is associated with cancer risk in adults(51). In recent years, novel studies have 
discovered the phenotypic status and functionality of NK cells in tumor site and also in 
peripheral blood of cancer patients. Research has shown that only a few infiltrating NK cells 
which are unlikely to greatly contribute to eliminate the tumoe cells(52). Due to NK’s 
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inefficient homing into malignant tissues, the situation may be overcome by cytokine-
mediated activation in immunotherapeutical regimen(53). However, novel studies of tumor-
associated NK cells demonstrated a striking phenotype, supporting the notion that tumor-
induced alterations of activating NK cell receptor expression may hamper immune 
surveillance and promote tumor progression.  
Bhat R reported the finding:besides its intrinsic oncolytic activity, parvovirus H-1PV is able 
to enhance NK cell-mediated killing of pancreatic adenocarcinoma cells. The experiment 
show that H-1PV infection of Panc-1 cells increases NK cell capacity to release IFN-Ǆ, TNF-ǂ 
and MIP-1ǂ/ǃ. Multiple activating receptors are involved in the NK cell-mediated killing of 
Panc-1 cells. Indeed, blocking of the natural cytotoxicity receptors-NKp30, 44 and 46 in 
combination, and NKG2D and DNAM1 alone inhibit the killing of Panc-1 cells. 
Interestingly, H-1PV infection of Panc-1 cells overcomes the part of inhibitory effects 
suggesting that parvovirus may induce additional NK cell ligands on Panc-1 cells. The 
enhanced sensitivity of H-1PV-infected pancreatic adenocarcinoma cells to NK cell-
dependent killing could be traced back to the upregulation of the DNAM-1 ligand, CD155 
and to the downregulation of MHC class I expression. The data suggests that NK cells 
display antitumor potential against PDAC and that H-1PV-based oncolytic immunotherapy 
could further boost NK cell-mediated immune responses and help to develop a 
combinatorial therapeutic approach against pancreatic cancer(54).  
NK cells can eliminate tumor cells through their ability to mediate antibody-dependent 
cellular cytotoxicity(ADCC). Nk cell recognition of an antibody-coated target cell results in 
rapid NK cell activation and degranulation(55). NK-cell mediated ADCC play a part in 
mechanisms of tumor-targeted mAbs which targeting CD20, Her2/neu, epidermal growth 
factor receptor(EGFR)(56)(57). Because HLA class レis a ligand for inhibitory receptor family, 
killer cell immunoglobulin-like receptor of NK cells(58), loss of HLA class レexpression can 
lead to escape of antigen-dependent cytotoxicity of CD8+ CTL and increase the possibility 
as a target of NK cell cytotoxicity. In pancreatic cancer, total HLA class レ loss is 6% in 
primary versus 43% in metastastic tumors;0 in G1, 33% in G2 and 67% in G3(59).  
In research of nonspecific immunotherapy, many cytokines were used to elevate the ability 
of the immune system. it is possible to activate tumor-specific antitumor immune responses 
by systemic injection of cytokine or introduction of cytokine gene into tumors through 
activating natural killer(NK) cells and tumor-specific CD4+ T cells and cytotoxic T 
lymphocytes(CTL). Different cytokines may stimulate antitumor immune responses by 
different mechanisms.  
Granulocyte Marcophage Colony-Stimulating Factor(GM-CSF) and IL-2 are the most 
popular cytokines used in cancer immunotherapy. GM-CSF, which can stimulate bone 
marrows differentiating and maturing to neutrophils, monocytes and dendritic cells, is used 
to generate cancer immunotherapy called GAVX(60). In clinical trials using the GAVX, 
induction of systemic antitumor immune response and clinical activity was observed in 
pancreatic cancer, melanoma, and renal cell carcinoma. In a study of combination of 
chemotherapy and immunotherapy, two GM-CSF secreting pancreas cancer cell lines 
(CG8020/CG2505) as immunotherapy were administered alone or in sequence with Cy in 
patients with advanced pancreatic cancer. Results showed GM-CSF secreting pancreas 
cancer cell lines demonstrated minimal treatment-related toxicity in patients with advanced 
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pancreatic cancer. Also, mesothelin specific T cell responses are detected/enhanced in some 
patients treated with CG8020/CG2505 immunotherapy. In addition, Cy modulated 
immunotherapy resulted in median survival in a Gemzar resistant population similar to 
chemotherapy alone(61).  
Interlukin-2 (IL-2) is a growth factor that stimulates innate immunity cells. Different dose of 
IL-2 has been proved either enhance or decrease cellular and humoral immune functions. 
Rosenberg used it developing lymphokine-activated killer(LAK) therapy for cancer(62). In a 
randomized study, preoperative subcutaneously IL-2 immunotherapy at 12 million IU for 3 
consecutive days before surgery is able to abrogate the effects of the surgical trauma and 
recover a normal immunofunction in pancreatic cancer patients(63). Recombinant 
interleukin-2 (rIL-2) was used in a study which aimed to evaluate the toxicity of pre- and 
postoperative rIL-2 treatment and the effects on innate immunity both in peripheral blood 
and in cancer tissue of patients with resectable pancreatic adenocarcinoma. Seventeen 
patients received high dose rIL-2 preoperative subcutaneous administration and two low 
dose postoperative cycles. NK cell and eosinophil count were evaluated in blood and in 
pancreatic surgical specimens. The result showed toxicity was moderate. In the early 
postoperative period, blood NK cells and eosinophils significantly increased compared to 
basal values (p < 0.02). Preoperative high dose rIL-2 administration is able to counteract 
surgery-induced deficiency of NK cells and eosinophils in peripheral blood in the early 
postoperative period, although it cannot overcome local mechanisms of immune tumor 
escape in cancer tissue. The amplification of innate immunity, induced by immunotherapy, 
may improve the control of metastatic cells spreading in the perioperative period(64).  
As a bridge between innate and adaptive immune response(65), IL-12 is independently 
identified as natural killer-stimulating factor (NKSF) and cytotoxic lymphocyte maturation 
factor(66), which induces proliferation of NK and T1 cells and production of cytokines, 
especially IFN-Ǆ，and also enhances the generation and activity of CTLs, through activation 
of STAT4(67).  
The combination of IL-12 and IL-27 can modify the polarization of Th2 effectors by both 
reduction of IL-5, GM-CSF and IL-13 and induction of IFN-gamma production, which lasted 
after cytokine removal. Besides, the combined treatment functionally modulated the Th2 
polarization of CEA-specific CD4(+) T cells and enhanced pre-existing Th1 type 
immunity(68).  
In recent study, IL-12 was coformulated with the biodegradable polysaccharide chitosan 
which could enhance the antitumor activity of IL-12 while limiting its systemic toxicity. 
Antitumor efficacy of IL-12 alone and IL-12 coformulated with chitosan (chitosan/IL-12) 
was assessed in mice bearing established pancreatic (Panc02) tumors. Additional studies 
involving depletion of immune cell subsets, tumor rechallenge, and CTL activity were 
designed to elucidate mechanisms of regression and tumor-specific immunity. 
Coformulation with chitosan increased local IL-12 retention from 1 to 2 days to 5 to 6 days. 
Weekly i. t. injections of IL-12 alone eradicated ≤10% of established Panc02 tumors, while i. 
t. chitosan/IL-12 immunotherapy caused complete tumor regression in 80% to 100% of 
mice. Depletion of CD4(+) or Gr-1(+) cells had no impact on chitosan/IL-12-mediated tumor 
regression. However, CD8(+) or NK cell depletion completely abrogated antitumor activity. 
I. t. chitosan/IL-12 immunotherapy generated systemic tumor-specific immunity, as >80% 
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of mice cured with i. t. chitosan/IL-12 immunotherapy were at least partially protected from 
tumor rechallenge. Furthermore, CTLs from spleens of cured mice lysed MC32a and gp70 
peptide-loaded targets. The reasearch has demonstrated Chitosan/IL-12 immunotherapy 
increased local retention of IL-12 in the tumor microenvironment, eradicated established, 
aggressive murine tumors, and generated systemic tumor-specific protective immunity(69).  
4. Specific immunotherapy 
Specific immunotherapy, which seems be more important in cancer treatment research, 
could be divide into 3 parts:monoclonal antibody, adoptive cellular therapy, and vaccine. 
Infusion of antibody or activated cells is called Passive Immunotherapy, on the other, 
vaccine can induce active immunotherapy. The simplest model of immune cell-mediated 
antigen-specific tumor rejection consists of three elements: appropriate antigen specific for 
the tumor, efficient antigen presentation and the generation of potent effector cells.  
4.1 Active immunotherapy 
Vaccine: The development of human therapeutic cancer vaccines has come a long way since 
the discovery of major histocompatability complex (MHC) restricted tumor antigens. As an 
new method to reconsituting immunity, cancer vaccionation can actively harness the 
intrinsic power of the immne system to recognize and destroy tumors. The ideal designed 
vaccine should actively generate antigen-specific immune response to abnomal protein 
expressed in tumor cells, including activating distinct components of the immune 
system:antigen presenting cells, B cells and T cells, producing the advantages of high 
specificity, minimal toxicity and permanently effective immunologic memory. Antigen 
could be delivered in the form of DNA or peptide, as well as tumor cells or antigen-pulsed 
DCs.  
GM-CSF is an important growth factor for granulocytes and monocytes, and has a crucial 
role in the growth and differentiation of DCs. Kimura M has found in vivo growth of AsPC-
1 cells, which retrovirally transduced with the GM-CSF gene, was inhabited and associated 
with increased survival of the nude mice(70).  
A series of clinical trails have been reported by researchers in John Hopkins in recent 10 
years. Jaffee et al conducted a phase レ study using allogeneic GM-CSF-secreting whole-cell 
tumor vaccine for pancreatic cancer. As vaccines, Two pancreatic cancer lines(PANC 10.05 
and 6.03), which had been genetically modified to express GM-CSF, were given to patients 
who had undergone pancreaticoduodenectomy eight weeks prior. Three of the eight 
patients who received ≥10×107 vaccine cells developed post-vaccination delayed-type 
hypersensitivity (DTH) responses associated with increased disease free survival time, and 
remained disease-free for longer than 25 months after diagnosis. Side effects were mainly 
limited to local skin reactions at the site of vaccination(71). Further phase ロ study of 60 
patients with resected pancreatic adenocarcinoma, patients received five treatments of 
2.5×108 vaccine cells, together with 5-Fu and radiotherapy. The reported median survival 
was 26 months, with a 1- and 2-year survival of 88% and 76% respectively(72). In latest 
report, a single institution phase ロ study of 60 patients with resected pancreatic 
adenocarcinoma was performed, each treatment consisted of a total of 5×108 GM-CSF-
secreting cells distributed equally among 3 lymph node regions. Subsequently, had received 
www.intechopen.com
 
Immunotherapy of the Pancreatic Cancer 
 
119 
5-FU based chemoradiation, patient received 5 immunotherapy. The median disease-free 
survival was 17.3 months with median survival of 24.8 months. The administration of 
immunotherapy was well tolerated. Besides, the postimmunotherapy induction of 
mesothelin-specific CD8+ T cells in HLA-A1+ and HLA-A2+ patients correlates with 
disease-free survival. The research concluded that an immunotherapy approach intergated 
with chemoradiation is safe and helpful for resected pancreas cancer(73).  
VEGF Vascular endothelial growth factor receptor 2 (VEGFR2) is an essential factor in 
tumor angiogenesis and in the growth of pancreatic cancer. Immunotherapy using epitope 
peptide for VEGFR2 (VEGFR2-169) is expected to improve the clinical outcome. A phase I 
clinical trial combining of VEGFR2-169 with gemcitabine was conducted for patients with 
metastatic and unresectable pancreatic cancer. Gemcitabine was administered at a dose of 
1000 mg/m(2) on days 1, 8, and 15 in a 28-day cycle. The VEGFR2-169 peptide was 
subcutaneously injected weekly in a dose-escalation manner (doses of 0.5, 1, and 2 
mg/body, six patients/one cohort). No severe adverse effect of grade 4 or higher was 
observed. Of the 18 patients who completed at least one course of the treatment, 15 (83%) 
developed immunological reactions at the injection sites. Specific cytotoxic T lymphocytes 
(CTL) reacting to the VEGFR2-169 peptide were induced in 11 (61%) of the 18 patients. The 
disease control rate was 67%, and the median overall survival time was 8. 7 months. This 
combination therapy for pancreatic cancer patients was tolerable at all doses. Peptide-
specific CTL could be induced by the VEGFR2-169 peptide vaccine at a high rate, even in 
combination with gemcitabine. From an immunological point of view, the optimal dose for 
further clinical trials might be 2 mg/body or higher(74).  
Ras peptide is the first agent tested in immunetherapy in pancreatic cancer. Gjertsen used 
an intradermal vaccine of APCs loaded ex vivo with synthetic ras peptide corresponding to 
the mutation found in patients. In this phase I/II trial , two of five patients with advanced 
pancreatic cancer showed induced immune response(75). In further phase I/II trial in 48 
pancreatic cancer patients with different clinic stages, ras peptide in combination with GM-
CSF could induce peptide-specific immunty in 58% patients. Compared to non-responders, 
survival time were prolonged in patients with advanced disease, the association between 
prolonged survival and an immune response against the vaccine suggests that a clinical 
benefit of ras peptide vaccination may be obtained for this group of patients(76).  
In 24 Patients with resected pancreatic cancer, with K-ras mutations at codon 12, were 
vaccinated once monthly for 3 months with a 21-mer peptide vaccine containing the 
corresponding K-ras mutation of the patient's tumor. Immune responses were evaluated by 
delayed-type hypersensitivity (DTH) tests and the enzyme-linked immunosorbent spot 
assays. Results showed there were no grade 3-5 vaccine-specific toxicities. The only National 
Cancer Institute grade 1 and 2 toxicity was erythema at the injection site (94%). Nine 
patients (25%) were evaluable for immunologic responses. One patient (11%) had a 
detectable immune response specific to the patient's K-ras mutation, as assessed by DTH. 
Three patients (13%) displayed a DTH response that was not specific. Median recurrence 
free survival time was 8. 6 months (95% confidence interval, 2.96-19.2) and median overall 
survival time was 20. 3 months (95% confidence interval, 11.6-45.3). It suggested K-ras 
vaccination for patients with resectable pancreatic adenocarcinoma proved to be safe and 
tolerable with however no elicitable immunogenicity and unproven efficacy(77).  
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In another phase ロstudy, a specific mutant ras peptide vaccine was tested as an adjuvant 
immunotherapy in pancreatic and colorectal cancer patients. Five pancreatic and seven 
colorectal cancer patients were vaccinated subcutaneously with 13-mer mutant ras peptide, 
corresponding to their tumor's ras mutation. Vaccinations were given every 4 weeks, up to a 
total of six vaccines. The result showed no serious acute or delayed systemic side effects 
were seen. Five out of eleven patients showed a positive immune response. Furthermore, 
the five pancreatic cancer patients have shown a mean disease-free survival (DFS) of 35. 2+ 
months and a mean overall survival (OS) of 44.4+ months. The study suggested it is feasible 
to use mutant ras vaccine in the adjuvant setting. This vaccine is safe, can induce specific 
immune responses, and it appears to have a positive outcome in overall survival(78). In a 
follow-up study, Twenty-three patients who were vaccinated after surgical resection for 
pancreatic adenocarcinoma (22 pancreaticoduodenectomies, one distal resection). The 
vaccine was composed of long synthetic mutant ras peptides designed mainly to elicit T-
helper responses. Seventeen of 20 evaluable patients (85%) responded immunologically to 
the vaccine. Median survival for all patients was 27.5 months and 28 months for immune 
responders. The 5-year survival was 22% and 29%, respectively. Strikingly, 10-year survival 
was 20% (four patients out of 20 evaluable) versus zero (0/87) in a cohort of nonvaccinated 
patient treated in the same period. Three patients mounted a memory response up to 9 years 
after vaccination. The observation indicates that K-ras vaccination may consolidate the effect 
of surgery and represent an adjuvant treatment option for the future(79).  
MUC1 In order to create MUC1-specific immune response, a vaccine composed of MUC1 
peptide and SBAS2 adjuvant was tested in a phase レstudy, There was an increase in the 
percentage of CD8+ T cells and MUC1-specific antibody(80).  
The other approach to induce MUC1-specific immune response is antigen-pulsed DCs. A 
Phase I/II clinical trial of a MUC1 peptide-loaded DC vaccine was carried out in 12 
pancreatic and biliary cancer patients following resection of their primary tumors. The 
vaccine was well tolerated and no toxicity was observed. Prior to vaccination, patients 
entered onto this trial had a significantly higher percentage of FoxP3+CD4+T cells 
compared to age matched healthy controls. The percentage of these cells also increased 
transiently following each injection, returning to baseline or below before the next injection. 
Vaccinated patients have been followed for over four years and four of the twelve patients 
are alive, all without evidence of recurrence(81).  
Another phase I/II trial used human autologous DCs transfected with MUC1 cDNA as 
vaccine, 4 of 10 patients showed a two- to ten-fold increase in the frequency of mucin-
specific IFN-Ǆ-secreting CD8+ T cells, suggesting an immune response(82). But in a phase Ⅲ 
trial of 255 patients using vaccine consisted of recombinant vaccinia and fowlpox viruses 
coexpressing CEA/MUC1/TRICOM, researchers failed to improve overall survival 
compared to palliative chemotherapy or best supportive care(83).  
In Kondo H’s clinical trial, Peripheral blood mononuclear cells (PBMCs) of twenty patients 
with unresectable or recurrent pancreatic cancer were separated into adherent cells for 
induction of MUC1-DCs and floating cells for MUC1-CTLs. MUC1-DCs were generated by 
culture with granulocyte monocyte colony stimulating factor (GM-CSF) and interleukin-4 
(IL-4) and then exposed to MUC1 peptide and TNF-alpha. MUC1-CTLs were induced by co-
culture with YPK-1 and then with interleukin-2 (IL-2). MUC1-DCs were injected 
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intradermally and MUC1-CTLs were given intravenously. The result showed one patient 
with multiple lung metastases experienced a complete response. Five patients had stable 
disease. The mean survival time was 9.8 months. No grade II-IV toxicity was observed. The 
research suggested adoptive immunotherapy with MUC1-DC and MUC1-CTL may be 
feasible and effective for pancreatic cancer(84).  
Mesothelin It is first reported by Thomas that specific CD8+ T-cell response which targeting 
mesothelin epitopes in pancreatic cancer can be induced via cross-presentation by an 
approach that recruits APCs to the vaccination site(85). Combinated with anti-glucocorticoid-
induced TNF receptor antibody (anti-GITR), the mesotheline DNA vaccine can induce 
immune pretection in mice with sungeneic mesothelin-expressing pancreatic cancer. 50% of 
animals treated with mesothelin were tumor-free 25 days after tumor injection compared to 
0 in untreated mice(86).  
DNA vaccines employing single-chain trimers (SCT) have been shown to bypass antigen 
processing and presentation and result in significant enhancement of DNA vaccine potency. 
In a study, a DNA vaccine employing an SCT targeting human mesothelin and 
characterized the ensuing antigen-specific CD8+ T cell-mediated immune responses and 
anti-tumor effects against human mesothelin-expressing tumors in HLA-A2 transgenic 
mice. The results showed that vaccination with DNA employing an SCT of HLA-A2 linked 
to human mesothelin epitope aa540-549 (pcDNA3-Hmeso540-beta2m-A2) generated strong 
human mesothelin peptide (aa540-549)-specific CD8+ T cell immune responses in HLA-A2 
transgenic mice. Vaccination with pcDNA3-Hmeso540-beta2m-A2 prevented the growth of 
HLA-A2 positive human mesothelin-expressing tumor cell lines in HLA-A2 transgenic mice 
in contrast to vaccination with DNA encoding SCT linked to OVA CTL epitope. Thus, the 
employment of SCT of HLA-A2 linked to the human mesothelin epitope aa540-549 
represents a potential opportunity for the clinical translation of DNA vaccines against 
human mesothelin-expressing tumors, including pancreatic cancer(87).  
4.2 Passive immunotherapy 
Passive immunotherapy could be accomplished by infusion monoantibody and tumor 
specific T-cell which was actived in vitro. With advances in structural and functional 
genomics, recent work has focused on targeted molecular therapy using monoclonal 
antibodies. Many monoantibodies were used to target molecules on the tumor cell surface 
and normal tissue stroma, which are related to pancreatic cancer oncogenesis, tumor growth 
or resistance to chemotherapy, as well as molecules involved in regulating inflammation 
and host immunoresponses. Although progress made by monoantibody in pancreatic cancer 
treatment, especially in preclinical studies, its clinical application requires further 
investigation. Besides the function bind to target antigen to block the corresponding signal 
transduction pathways, antibody-dependent cellular cytotoxicity (ADCC) can also be 
observed in some pancreatic cancer cell lines.  
4.2.1 Antibody 
Monoclonal antibodies against human tumor targets were initially in rodents, which will 
induce immunologic responses from patient against mouse antibodies. With the 
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drvelopment of recombinant DNA technology, this problem was solved and chimeric 
antibodies, antibody fragments or intact fully human antibodies were produced and tested 
clinically. Base on moral principles, antibodies were used as adjunctive treement with 
chemotherapy agents, small molecule signal transduction inhibitors, or radiation in clinical 
trails, to study if can help patients lengthen the survival. The targets are generally classified 
into three major categories:cell surface proteins;antigen associated with the tumor 
stroma;antigen on tumor-associated vasculature and angiogenic ligands(88).  
4.2.1.1 Anti-EGFR antibodies 
Cetuximab is a chimeric mouse-human antibody against an epitope located in extra-celluar 
part of EGFR. In preclinical studies, cetuximab could decrease cell proliferation and 
phosphorylation of EGFR, and blocked the binding of the adaptor protein Grb2 to EGFR 
upon activation by EGF(89). Another preclinical study, the combination of cetuximab 
together with gemcitabine and radiation effectively prolonged the tumor xenograft volume 
doubling time (30.1±3.3days), compared with gemcitabine monotherapy (11.6±3.1days), 
radiation monotherapy (16.7±3.1days), cetuximab with gemcitabine (20.1±3.1days)and 
cetuximab with radiation (22.5±3.3days)(90).  
In many clinical trails, synergistic effects were observed using combination of cetuximab 
therapy and chemotherapy agents. In a multicenter phase II trial, Patients with measurable 
locally advanced or metastatic pancreatic cancer who had never received chemotherapy for 
their advanced disease and had immunohistochemical evidence of EGFR expression were 
treated with cetuximab at an initial dose of 400 mg/m(2), followed by 250 mg/m(2) weekly 
for 7 weeks. Gemcitabine was administered at 1,000 mg/m(2) for 7 weeks, followed by 1 
week of rest. In subsequent cycles, cetuximab was administered weekly, and gemcitabine 
was administered weekly for 3 weeks every 4 weeks. In sixty-one patients who were 
screened for EGFR expression, 58 patients (95%) had at least 1+ staining, and 41 were 
enrolled onto the trial, result showed Five patients (12.2%) achieved a partial response, and 
26 (63.4%) had stable disease. The median time to disease progression was 3.8 months, and 
the median overall survival duration was 7.1 months. One-year progression-free survival 
and overall survival rates were 12% and 31.7%, respectively. The most frequently reported 
grade 3 or 4 adverse events were neutropenia (39.0%), asthenia (22.0%), abdominal pain 
(22.0%), and thrombocytopenia (17.1%). Cetuximab in combination with gemcitabine 
showed promising activity against advanced pancreatic cancer(91).  
Another multicenter pahse ロ study which is combination treatment with cetuximab and 
gemcitabine/oxaliplatin. Patients which had histological or cytological diagnosis of 
metastatic pancreatic adenocarcinoma received cetuximab 400 mg m(-2) at first infusion 
followed by weekly 250 mg m(-2) combined with gemcitabine 1000 mg m(-2) as a 100 min 
infusion on day 1 and oxaliplatin 100 mg m(-2) as a 2-h infusion on day 2 every 2 weeks. The 
intention-to-treat analysis of 61 evaluable patients showed an overall response rate of 33%, 
including 1 (2%) complete and 19 (31%) partial remissions. There were 31% patients with 
stable and 36% with progressive disease or discontinuation of the therapy before re-staging. 
The presence of a grade 2 or higher skin rash was associated with a higher likelihood of 
achieving objective response. Median time to progression was 118 days, with a median 
overall survival of 213 days. A clinical benefit response was noted in 24 of the evaluable 61 
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patients (39%). Although the addition of cetuximab to the combination of gemcitabine and 
oxaliplatin is well tolerated, the reasearch failed to increase response or survival in patients 
with metastatic pancreatic cancer(92).  
But the effect of the cetuximab is limited by the affinity of expressed EGFR in pancreatic 
cancer, other factors including mutation of K-ras, PTEN expression or host complement 
level. these may be the reasons of failure in some trails. In a phase ロ trail, within the 
cetuximab group and noncetuximab group, no significant differences were found in 
objective response rate (17.5% Vs12.2%), median progression-free survival (3.4 months Vs 
4.2 months), median overall survival (7.5 months Vs 7.8 months)(93), The result can’t prove a 
synergistic effect in combination of cetuximab and gemcitabine/cisplatin treatment in 
pancreatic cancer.  
Another phase ヮ trail of Patients with unresectable locally advanced or metastatic 
pancreatic adenocarcinoma were randomly assigned to receive gemcitabine alone or 
gemcitabine plus cetuximab. A total of 745 eligible patients were accrued. No significant 
difference was seen between the two arms of the study with respect to the median survival 
time (6. 3 months for the gemcitabine plus cetuximab arm v5.9 months for the gemcitabine 
alone arm; hazard ratio = 1.06; 95% CI, 0.91 to 1.23; P = .23, one-sided). Objective responses 
and progression-free survival were similar in both arms of the study. Although time to 
treatment failure was longer in patients on gemcitabine plus cetuximab (P=.006), the 
difference in length of treatment was only 2 weeks longer in the combination arm. Among 
patients who were studied for tumoral EGFR expression, 90% were positive, with no 
treatment benefit detected in this patient subset. The author think in patients with advanced 
pancreas cancer, the anti-EGFR monoclonal antibody cetuximab did not improve the 
outcome compared with patients treated with gemcitabine alone. Alternate targets other 
than EGFR should be evaluated for new drug development(94).  
Matuzumab(EMD 72000) is a humanized IgG1 mAb against EGFR. Laboratory studies have 
shown promising inhibitory effects on tumor growth and angiogenesis, include L3. 6pl in an 
orthotopic rat model(95). In an phase レclinical trail, matuzumab was given at a dose of 400-
800 mg once weekly for 8 weeks, followed by gemcitabine 1000mg/m2 weekly for two 
cycles. The partial response or stable disease in 12 evaluated advanced pancreatic cancer 
patients was 66.7%(96).  
4.2.1.2 Anti-ErbB2/HER2 antibodies 
Trastuzumab(Herceptin) is a humanized mAb, which has shown significant growth 
inhibition of a pancreatic cancer cell line and xenografts established with the same line. In a 
study focusing on HER2 overexpressing pancreatic cancer, trastuzumab was combined with 
fluoropyrimidine S-1 to treat cancer cells in vivo and in vitro, pancreatic cell growth 
inhibition is observed not only by inhibition of the HER2 signal transduction pathway, but 
also by antibody-dependent cellular cytotoxicity(ADCC) induced by trastuzumab(97). In 
another research, although in four pancreatic cell lines, trastuzumab didn’t express inhibitor 
effect and synergistic effect with gemcitabine, ADCC were observed in three cells which 
expressed HER2 in mice. In Capan-1 xenografted mice, trastuzumab inhibited tumor growth 
significantly and prolonged survival(98).  
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Larbouret reported combination treatment of matuzumab and trastuzumab could enhance 
the inhibitory effect on HER2 phosphorylation, lead to significantly decrease xenograft 
tumor sizes or induce more complete remissions when compared to antibody alone, then 
prolonged survival in BxPC-3 and MIA PaCa-2 pancreatic cancer cells xenograft mice(99). 
The further study which took placed in nude mice, bearing human pancreatic carcinoma 
xenografts, combined anti-EGFR (cetuximab) and anti-HER2 (trastuzumab) or 
gemcitabine were given as trement and tumor growth was observed. Result showed in 
first-line therapy, mice survival was significantly longer in the 2mAbs group compared 
with gemcitabine (P<0.0001 for BxPC-3, P=0.0679 for MiaPaCa-2 and P=0.0019 for Capan-
1) and with controls (P<0.0001). In second-line therapy, tumor regressions were observed 
after replacing gemcitabine by 2mAbs treatment, resulting in significantly longer animal 
survival compared with mice receiving continuous gemcitabine injections (P=0.008 for 
BxPC-3, P=0.05 for MiaPaCa-2 and P<0.001 for Capan-1). Therapeutic benefit of 2mAbs 
was observed despite K-Ras mutation. Interestingly, concerning the mechanism of action, 
coinjection of F(ab')(2) fragments from 2mAbs induced significant tumor growth 
inhibition, compared with controls (P=0.001), indicating that the 2mAbs had an Fc 
fragment-independent direct action on tumor cells. This preclinical study demonstrated a 
significant improvement of survival and tumor regression in mice treated with anti-
EGFR/anti-HER2 2mAbs in first- and second-line treatments, compared with 
gemcitabine, independently of the K-Ras status(100).  
4.2.1.3 Anti-MUC1 antibodies 
PAM4 is a murine antibody to MUC1 obtained from mice immunized with purified mucin 
from a human pancreatic cancer xenograft sample. In a preclinical study, 90Yttrium-
labelled PAM4 monoclonal antibody was combined with gemcitabine in mice bearing 
Capan-1, the result showed increased inhibition of tumor growth and prolonged survival 
of the mice(101). The recent clinical trail took place in 21 patients with advanced pancreatic 
cancer. 111In-hPAM4 showed normal biodistribution with radiation dose estimates to red 
marrow and solid organs acceptable for radioimmunotherapy and with tumor targeting in 
12 patients. One patient withdrew before (90)Y-hPAM4; otherwise, 20 patients received 
(90)Y doses of 15 (n=7), 20 (n=9), and 25 mCi/m(2) (n=4). Treatment was well tolerated; 
the only significant drug-related toxicities were (NCI CTC v.3) grade 3 to 4 neutropenia 
and thrombocytopenia increasing with (90)Y dose. There were no bleeding events or 
serious infections, and most cytopenias recovered to grade 1 within 12 weeks. Three 
patients at 25 mCi/m(2) encountered dose-limiting toxicity with grade 4 cytopenias more 
than 7 days, establishing 20 mCi/m(2) as the maximal tolerated (90)Y dose. Two patients 
developed HAHA of uncertain clinical significance. Most patients progressed rapidly and 
with CA19-9 levels increasing within 1 month of therapy, but 7 remained progression-free 
by CT for 1.5 to 5.6 months, including 3 achieving transient partial responses (32%-52% 
tumor diameter shrinkage). The study concluded (90)Y-Clivatuzumab tetraxetan was well 
tolerated with manageable hematologic toxicity at the maximal tolerated (90)Y dose, and 
is a potential new therapeutic for advanced pancreatic cancer(102).  
In a Phase レtrial for patients with stage ヮ and ワ pancreatic cancer, another antibody C595, 
which is targeting the protein core of MUC1, was conjugated with the ǂ-particle-emitting 
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213bismuch. In vitro study showed specific cytotoxic to MUC1-expressing pancreatic cancer 
cells in a concentration-dependent manner compared to controls(103).  
4.2.1.4 Anti-mesothelin antibodies 
SS1P is a recombinant immunotoxin that consists of an anti-mesothelin scFv(ss1) fused to 
PE38, a 38Kda portion of Pseudomonas exotoxin. Sing-chain Fv(scFv)v was isolated from a 
phage display library obtained from the spleen of mice immunized with mesothelin-
expression plasmid. After binding to mesothelin and subsequent internalisation into cells, it 
inhibits protein synthesis and results in apoptosis.  
In preclinical study, SS1P plus radition in treating mesothelin-expressing tumor xenografts, 
combination treatment significantly prolonged the doubling time of tumors(104);meanwhile, 
synergic result was observed when treat with gemcitabin, the tumors were induced 
regression completely(105).  
In the further phase レ clinical study, SS1P was administered by intravenous infusion in 34 
patients with mesothelin-expressing tumor, including 2 pancreatic cancer patients, the 
results showed that it was well-tolerated with self-limiting pleuritis as dose-limiting toxicity, 
12% tumor size decresed from 20-50% and lasted for more than 4 weeks, 56% patients 
showed stable disease and 29% of the patients had progressive disease(106).  
Another monoclonal antibody against mesothelin, MORAb-009, is a chimeric of a mouse 
and human mAb derived from a phage-display library and re-engineered(107). In a phase I 
clinical trial, treatment of MORAb-009 in patients with advanced mesothelin-expressing 
cancers has been determined if safety, dose-limiting toxicity (DLT), and maximum tolerated 
dose (MTD). A total of 24 subjects were treated including 13 mesothelioma, 7 pancreatic 
cancer, and 4 ovarian cancer patients. The median number of MORAb-009 infusions was 4 
(range 1-24 infusions). At the 400 mg/m(2) dose level, 2 subjects experienced DLT (grade 4 
transaminitis and a grade 3 serum sickness). Thus, although there were other contributing 
causes of these adverse events, 200 mg/m(2) was considered the MTD. Other adverse events 
at least possibly related to MORAb-009 included 7 drug hypersensitivity events (all grade 1 
or 2) and a thromboembolic event (grade 4). Eleven subjects had stable disease. There was a 
dose-dependent increase in serum MORAb-009 concentration. The result suggested that 
MORAb-009 is well tolerated and the MTD when administered weekly is conservatively set 
at 200 mg/m(2). Phase II studies of MORAb-009 in different mesothelin-expressing cancers 
are ongoing(108).  
4.2.2 Adoptive cell transfer 
In cellular antitumor immunity, T-cells must first be activated by bone marrow—derived 
APCs that present tumor antigens and provide essential co-stimulatory signals, migrate and 
gain access to the tumor microenvironment, and overcome obstacles to effective triggering 
posed by the tumor. Dendritic cells, which are the strongest antigen presenting cells in the 
body. Their generation for anti-tumor immunity has been the focus of a vast array of 
scientific and clinical studies. DC’s specialized capacity to cross-present exogenous Ags onto 
major histocompatability (MHC) class I molecules for the generation of T-Ag-specific 
cytotoxic T lymphocytes (CTLs) has made it possible to produce actived T cell in vitro and 
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in vivo. Adoptive immunotherapy involves harvesting the patient’s peripheral blood T-
lymphocytes, stimulating and expanding the autologous tumor-reactive T-cells, finally 
transferring them back into the patient.  
4.2.2.1 K-ras-specific CTLs 
In vitro, Immature DCs had pulsed with synthesized mutant K-ras peptide (YKLVVVGAV). 
When the DCs were matured, Kras antigen epitope can express on the DC's surface 
effectively and Cytotoxic T lymphocytes (CTLs) can be induced when autogeneic and 
homologous T cells co-cultured with the mutant K-ras peptide-pulsed DCs. The reasearch 
demonstrated the induced CTLs can kill the pancreatic cancer cell line Patu8988 which 
expresss the same K-ras mutation type effectively in virto and in vivo. Without damage the 
normal tissue cells, the killing rate of activated K-ras specific CTLs to the tumor cell when 
the ratios of CTL: Patu8988 cells were 10:1, 20:1, and 50:1 were (21.2+/-1.9)%, (32.4 +/-
2.1)%, and (45.7+/-5.3)% respectively, all while the killing efficiency significantly superior 
to those of the non-specific activated T lymphocyte (all P < 0.05). Eight days after CTL 
injection into the nude mice the tumor size of the intratumor injection group was (68 +/-
13) mm3, significantly smaller than those of the control group and IL-2 activated non-
specific CTL intra-tumor injection group [(87+/-14) mm3 and (79 +/- 19) mm3, both P < 
0.05]. The survival rates of the nude mice of the K-ras specific CTL intra-tumor injection 
group, CTL caudal vein injection group, and IL-2 activated non-specific CTL intra-tumor 
injection group were all significantly higher than that of the control group (all P < 0.05), 
and the survival rate of the K-ras specific CTL intra-tumor injection group was 
significantly higher than that of the IL-2 activated non-specific CTL intra-tumor injection 
group (P <0.05). Immunohistochemical staining confirmed that K-ras specific CTL had the 
ability to move toward tumor. The result showed antigen-specific-CTLs induced in virto 
and transferred into the patient can used be a effective treatment for pancreatic cancer(109).  
4.2.2.2 MUC1-specific CTLs  
In MUC1 expressing Tumor-bearing mice , there were low affinity MUC1-specific CTLs that 
have no effect on the spontaneously occurring pancreatic tumors in vivo. However, 
adoptive transfer of these CTLs was able to completely eradicate MUC1-expressing 
injectable tumors in MUC1 transgenic mice, and these mice developed long-term immunity. 
These CTLs were MHC class I restricted and recognized peptide epitopes in the 
immunodominant tandem repeat region of MUC1. The MET mice appropriately mimic the 
human condition and are an excellent model with which to elucidate the native immune 
responses that develop during tumor progression and to develop effective antitumor 
vaccine strategies(110).  
In a study of 11 patients with lung metastases from different cancer, CTLs were generated in 
virto using cultured DCs, synthetic peptide, peripheral blood lymphocytes, IL-2 and anti-
CD3 antibody. The patients received either Muc-1, CEA, gpl00, Her-2 or SART-3-PDAK cells 
generated in vitro, All transfers of peptide-pulsed dendritic cell-activated killer(PDAK) cells, 
which showed peptide/HLA-specific lysis, were well-tolerated in all patients, and adverse 
effects (elevation of transaminase, fever, and headache) were observed primarily at grade 1, 
but in no case greater than grade 2. One partial response (PR) of lung metastasis occurred in 
a pancreatic cancer patient who received 3x10(7) Muc-1-PDAK cells/kg. The cytolytic units 
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of PDAK cells in this patient appeared to be substantially higher compared to those in PD 
patients. The results suggest that adoptive immunotherapy using PDAK cells for cancer 
patients with antigen-positive lung metastasis is safe and feasible(111).  
However, in another clinical study, data demonstrate that MUC1 peptide-based 
immunization elicits mature MUC1-specific CTLs in the peripheral lymphoid organs. The 
mature CTLs secrete IFN-gamma and are cytolytic against MUC1-expressing tumor cells in 
vitro. Unfortunately, active CTLs that infiltrate the pancreas tumor microenvironment 
become cytolytically anergic and are tolerized to MUC1 antigen, allowing the tumor to 
grow. The CTL tolerance could be reversed at least in vitro with the use of anti-CD40 co-
stimulation. The pancreas tumor cells secrete immunosuppressive cytokines, including IL-10 
and TGF-beta that are partly responsible for the down-regulation of CTL activity. In 
addition, they down-regulate their MHC class I molecules to avoid immune recognition. 
CD4+CD25+T regulatory cells, which secrete IL-10, were also found in the tumor 
environment. Together these data indicate the use of several immune evasion mechanisms 
by tumor cells to evade CTL killing. Thus altering the tumor microenvironment to make it 
more conducive to CTL killing may be key in developing a successful anti-cancer 
immunotherapy(112).  
4.2.2.3 Telomerase-specific CTLs  
In a syngeneic pancreatic tumor mouse model, T-cells were produced in vitro by coculturing 
human lymphocytes with telomerase peptide-pulsed dendritic cells(DCs) or in vivo by 
injection of peptide, animals treated with telomerase-specific T cells showed significantly 
delayed disease progression(113).  
4.2.2.4 Mesothelin-specific CTLs 
With the identification of novel mesothelin CTL epitopes, T-cell lines generated from one of 
these epitopes were shown to lyse pancreatic tumor cells. Several agonist epitopes were 
defined and were shown to (a) have higher affinity and avidity for HLA-A2, (b) activate 
mesothelin-specific T cells from normal individuals or cancer patients to a greater degree 
than the native epitope in terms of induction of higher levels of IFN-gamma and the 
chemokine lymphotactin, and (c) lyse several mesothelin-expressing tumor types in a MHC-
restricted manner more effectively than T cells generated using the native peptide. External 
beam radiation of tumor cells at nontoxic levels was shown to enhance the expression of 
mesothelin and other accessory molecules, resulting in a modest but statistically significant 
increase in tumor cell lysis by mesothelin-specific T cells. The result supports and extends 
observations that mesothelin is a potential target for immunotherapy of pancreatic cancers, 
as well as mesotheliomas. Combination of immunotherapy and chemoradiotherapy may be 
a better choice for the patients(114).  
4.3 Future perspective 
Although it is used as adjuvant treatment in preclinical or clinical trail, immunotherapy may 
be the next great hope for pancreatic cancer treatment. While monoclonal antibodies, 
cytokines, vaccines and CTL have individually shown some promise, it’s hard to say which 
is better in nonspecific and specific immunotherapy. It seems to be the best strategy to 
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obtained more efficient results in combination with a variety of antigens, or vaccine and 
antibody combinations. A nonspecific and specific immunotherapy combination offers 
another potent strategy. With the combination, the ultimate achievable goal may be a 
durable anti-tumor immune response that can destory and prevent it from recurrence over 
the course of a patient’s life.  
According to the existed profiles, The key of the immunotherapy on pancreatic cancer is to 
break through cancer microenvironment’s defence. Suppressing the function of immuno-
suppression cells, such as immunosuppressive tumor-associated macrophages (TAMs), 
myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs) reside in tumors 
is as important as inducing the specific immune agent, such as antibody or CTL.  
Combating with each other, tumor and immune system are like two warriors on the other 
side of balance. What we can do is to break the balance and help the immune system win 
the war. Traditional methods, surgical operation, chemoradiation, can decrease the 
number of the tumor cells to the minimum while do harmful to immune system in the 
same time. So as the followed treatment, the passive immunotherapy may be the best 
choice to supply enough actived immune agents in a short period to kill the metastatic 
cancer cells. When patient recovered, Cytokines and vaccine will help to establish long -
term specific immune response to keep watch on and get rid of residuary cancer cells. 
Owing to pancreatic cancer cells expressing different abnormal antigens, the combination 
of 2 or more epitopes vaccines will obstain better effect to prevent from recurrence. and 
metastasis.  
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disease. As pancreatic cancer suffers from lack of early diagnosis or prognosis markers, this book
encompasses stem cell and genetic makers to identify the disease in early stages. The book uncovers the
rationale and effectiveness of monotherapy and combination therapy in combating the devastating disease. As
immunotherapy is emerging as an attractive approach to cease pancreatic cancer progression, the present
book covers various aspects of immunotherapy including innate, adaptive, active, passive and bacterial
approaches. Management of anesthesia during surgery and pain after surgery has been discussed. Book also
takes the reader through the role of endoscopy and fine needle guided biopsies in diagnosing and observing
the disease progression.
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